Rotavirus prophylaxis market top players, rotavirus prophylaxis market share, rotavirus prophylaxis market size, rotavirus prophylaxis market research, rotavirus prophylaxis market outlook, rotavirus prophylaxis market segments, rotavirus prophylaxis market overview, rotavirus prophylaxis industry analysis, rotavirus prophylaxis market trends, rotavirus prophylaxis market insights
The rotavirus prophylaxis global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Rotavirus Prophylaxis Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The rotavirus prophylaxis market size has grown rapidly in recent years. It will grow from $8.15 billion in 2023 to $9.05 billion in 2024 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to vaccine access and equity, emerging rotavirus strains, r&d investments, public health preparedness.
The rotavirus prophylaxis market size is expected to see strong growth in the next few years. It will grow to $13.24 billion in 2028 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to gastrointestinal disease burden, global expansion, vaccination programs, vaccine confidence. Major trends in the forecast period include next-generation vaccines, combination vaccines, vaccine delivery innovation, global immunization collaboration.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/rotavirus-prophylaxis-global-market-report
Scope Of Rotavirus Prophylaxis Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Rotavirus Prophylaxis Market Overview
Market Drivers –
The increasing vaccine courses are expected to propel the growth of the rotavirus prophylaxis market going forward. A vaccine course is a specific dose of vaccine that is meant to be given to a person to produce protection from a particular disease. The vaccine course dosage stimulates the immunological response, providing excellent protection against rotavirus infection. This increased immunity minimizes the risk of diseases and improves the vaccine’s overall efficacy. For instance, in January 2022, according to a report published by the United Nations International Children’s Emergency Fund (UNICEF), a US-based provider of humanitarian and developmental help to children, around 5.71 million courses of RV1-5 frozen rotavirus vaccine were produced 2022, with a projected increase to 9.31 million courses by 2028. Furthermore, 5.29 million courses of RV5-2 lyophilized rotavirus vaccines were manufactured in 2022, with a projected rise to 6.13 million courses by 2028. Therefore, the increasing number of vaccines will drive the rotavirus prophylaxis market.
Market Trends –
Major companies operating in the rotavirus prophylaxis market are developing vaccines to meet customer requirements. Vaccine approvals involve a rigorous process that includes multiple development and testing stages. These approvals are essential in ensuring that vaccines are safe and effective for preventing this viral illness, particularly in infants and young children. For instance, in November 2022, GlaxoSmithKline plc, a UK-based pharmaceutical and biotechnology company, announced that the Food and Drug Administration (FDA) had approved an oral-dosing applicator-only presentation (liquid formulation) of ROTARIX (Rotavirus Vaccine, Live and Oral), that prevents rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4 and G9) in infants. The novel oral-dosing applicator-only presentation is entirely liquid and must not be reconstituted before use. ROTARIX lyophilized and liquid formulations are administered orally in a two-dose series, contain the same live, human-attenuated rotavirus strain and are made using comparable techniques.
The rotavirus prophylaxis market covered in this report is segmented –
1) By Treatment: Rotarix; Rotavac; Rotavin-M1; Oral Rehydration Fluid; Other Treatments
2) By Route of Administration: Oral; Parenteral; Other Route of Administrations
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
Get an inside scoop of the rotavirus prophylaxis market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=13045&type=smp
Regional Insights –
North America was the largest region in the rotavirus prophylaxis market in 2023. The regions covered in rotavirus prophylaxis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies –
Major players in the rotavirus prophylaxis market are Pfizer Inc., Johnson & Johnson, Merck & Co., Novartis AG, Sanofi SA, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Sinovac Biotech Ltd., Astellas Pharma Inc., CSL Limited, Bharat Biotech International Limited, Daiichi Sankyo Co. Ltd., Lupin Limited, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India Pvt. Ltd., Zydus Lifescience Ltd., Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Biocad Biopharmaceutical Co., Bharat Serums and Vaccines Limited, Biological E Limited, PT Bio Farma, Panacea Biotec Ltd., Shanghai Institute of Biological Products (SIBP).
Table of Contents
1. Executive Summary
2. Rotavirus Prophylaxis Market Report Structure
3. Rotavirus Prophylaxis Market Trends And Strategies
4. Rotavirus Prophylaxis Market – Macro Economic Scenario
5. Rotavirus Prophylaxis Market Size And Growth
…..
27. Rotavirus Prophylaxis Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
